Zacks Investment Research upgraded Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to Hold in a report released today.
- Updated: October 11, 2016
Zacks Investment Research has upgraded Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to Hold in a statement released on 10/11/2016.
On Thursday September 08, 2016, Mizuho Securities released a statement for Adamas Pharmaceuticals Inc (NASDAQ:ADMS) upped the target price from $22.00 to $26.00. At the time, this indicated a possible upside of 0.66%.
Yesterday Adamas Pharmaceuticals Inc (NASDAQ:ADMS) traded -3.97% lower at $15.95. ADMS’s 50-day average is $15.91 and its two hundred day average is $15.82. With the last stock price close up 0.81% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Trade Volume was down over the average, with 170,850 shares of ADMS changing hands under the typical 246,332
Recent Performance Chart
Adamas Pharmaceuticals Inc has with a one year low of $12.02 and a one year high of $31.84 and has a market capitalization of $0.
Also covering Adamas Pharmaceuticals Inc's price target, a total of 8 brokers have issued a research note on the company. The average stock price target is $36.00 with 0 firms rating the stock a strong buy, 0 equity analysts rating the company a buy, zero brokerages rating the company a hold, zero analysts rating the company a underperform, and finally 0 brokers rating the stock a sell.
About Adamas Pharmaceuticals Inc (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. Its ADS-5102 is an extended-release version of amantadine that is intended for once daily administration at bedtime. It is developing ADS-8704, which is a fixed-dose combination of its controlled release version of memantine and donepezil for the treatment of moderate to severe dementia related to Alzheimer's disease. Its ADS 8902, a triple combination antiviral drug therapy for influenza. It also offers Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules (formerly MDX-8704) and Namenda XR (memantine hydrochloride) extended release capsules.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.